Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Could THUNDERBOLT sharpen Penumbra’s stroke portfolio before the Boston Scientific deal closes?
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy and computer assisted clot removal.
MeRT FDA clearance gives Wave Neuroscience a first-mover role in biomarker-guided PTSD care
Find out how Wave Neuroscience’s MeRT FDA clearance could reshape biomarker-guided neuromodulation for PTSD care.
Why Enliven’s FDA alignment may matter as ELVN-001 moves toward Phase 3
Find out how Enliven’s ELVN-001 data and FDA alignment could reshape the next phase of chronic myeloid leukemia therapy.
Humacyte (HUMA) posts positive Phase 3 dialysis access data, then raises $50m at a discount on the strength of it
Humacyte (HUMA) posts positive Phase 3 dialysis access data and raises $50M at a discount. FDA filing planned for H2 2026. Read the full executive analysis.
Why Cipla’s Goa facility VAI status matters more than a routine USFDA inspection update
Cipla has regulatory breathing room, but launches still matter. The Goa VAI status may decide how investors price its US growth story. Read more.
How a first-in-class HDV approval could support Gilead Sciences’ long-term antiviral portfolio
Find out how Hepcludex approval could strengthen Gilead Sciences’ antiviral portfolio and reshape HDV care in the U.S.
Avacta (AIM: AVCT) raises ÂŁ9m at no discount days after ASCO cancer data
Avacta (AIM: AVCT) raised ÂŁ9m at no discount just before a 30 June bond trigger, days after AVA6000 cancer data. Is this a turnaround or another clock ticking?
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
GSK Nuvalent acquisition puts $GSK in focus as $10.6bn oncology bet reshapes lung cancer pipeline
GSK is buying Nuvalent for USD 10.6bn to expand in lung cancer. Find out what the $GSK oncology deal means for investors.